Background
Background A genetic susceptibility to A genetic susceptibility to extrapyramidal symptoms caused by extrapyramidal symptoms caused by treatment with neuroleptic medication treatment with neuroleptic medication has been suggested. has been suggested.
Aims Aims To identify predictor variables for
To identify predictor variables for neuroleptic-induced extrapyramidal neuroleptic-induced extrapyramidal symptoms, particularly considering family symptoms, particularly considering family history of primary movement disorders. history of primary movement disorders.
Method Method We investigated100 in-
We investigated100 inpatients receiving a stable neuroleptic patients receiving a stable neuroleptic medication with regard to occurrence of medication with regard to occurrence of extrapyramidal symptoms, drug history extrapyramidal symptoms, drug history and detailed family history of primary and detailed family history of primary movement disorders. movement disorders.
Results

Step-wise logistic regression
Step-wise logistic regression analysis revealed that a positive family analysis revealed that a positive family history was a significant predictor for history was a significant predictor for lifetime prevalence of extrapyramidal lifetime prevalence of extrapyramidal symptoms, including reported and symptoms, including reported and currently observed symptoms.The currently observed symptoms.The duration of exposure to neuroleptic duration of exposure to neuroleptic medication and age were further medication and age were further predictors. predictors.
Conclusions Conclusions Our findings underline
Our findings underline the notion of genetic susceptibility for the notion of genetic susceptibility for secondary extrapyramidal symptoms and secondary extrapyramidal symptoms and suggest possible shared genetic factors in suggest possible shared genetic factors in primary and secondary movement primary and secondary movement disorders as well as psychotic disorders. disorders as well as psychotic disorders.
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Neuroleptic-induced extrapyramidal sympNeuroleptic-induced extrapyramidal symptoms often lead to non-compliance and toms often lead to non-compliance and consequently poorer treatment outcome consequently poorer treatment outcome (Gerlach, 2002) . Extrapyramidal symptoms (Gerlach, 2002) . Extrapyramidal symptoms may also occur with modern, atypical neumay also occur with modern, atypical neuroleptic medication (Tarsy roleptic medication (Tarsy et al et al, 2002) . , 2002). Risk factors include age, psychiatric diagRisk factors include age, psychiatric diagnosis, psychopathology, and dosage and nosis, psychopathology, and dosage and duration of neuroleptic exposure, but no duration of neuroleptic exposure, but no clear-cut predictor has been identified as clear-cut predictor has been identified as yet (Ayd, 1961; Swett, 1975 ; Nasrallah yet (Ayd, 1961; Swett, 1975; Nasrallah et al et al, 1988; Berardi , 1988; Berardi et al et al, 2000; Srinivasan , 2000; Srinivasan et al et al, 2001) . More recently, genetic factors , 2001 ). More recently, genetic factors have been suggested to have a role in the have been suggested to have a role in the susceptibility to extrapyramidal symptoms susceptibility to extrapyramidal symptoms (Basile (Basile et al et al, 2002; Segman , 2002; Segman et al et al, 2002) . , 2002). Given that a genetic predisposition may Given that a genetic predisposition may increase the susceptibility to such sympincrease the susceptibility to such symptoms, a positive family history of primary toms, a positive family history of primary movement disorders may be associated movement disorders may be associated with their development. An increasing with their development. An increasing number of polymorphisms in dystonia and number of polymorphisms in dystonia and parkinsonism genes have been shown to parkinsonism genes have been shown to be associated with primary movement be associated with primary movement disorders (Klein & Ozelius, 2002 ; Gasser, disorders (Klein & Ozelius, 2002; Gasser, 2003) . We therefore investigated whether 2003). We therefore investigated whether a family history of primary movement a family history of primary movement disorders might be a predictor of extradisorders might be a predictor of extrapyramidal symptoms in patients receiving pyramidal symptoms in patients receiving typical and atypical neuroleptic medication. typical and atypical neuroleptic medication.
METHOD METHOD Patients and diagnosis Patients and diagnosis
Participants were consecutively recruited Participants were consecutively recruited from people admitted as in-patients of the from people admitted as in-patients of the Department of Psychiatry and PsychotherDepartment of Psychiatry and Psychotherapy at the University of Lubeck. Each apy at the University of Lü beck. Each participant gave written informed consent participant gave written informed consent after having been carefully informed about after having been carefully informed about the study. The study was approved by the the study. The study was approved by the local ethics committee. Participants had to local ethics committee. Participants had to meet the following inclusion criteria: meet the following inclusion criteria:
(a) (a) stable neuroleptic medication for at stable neuroleptic medication for at least 1 week; least 1 week; Overall & Gorham, 1962) . Scale (BPRS; Overall & Gorham, 1962) . Each participant underwent a complete Each participant underwent a complete neurological examination with particular neurological examination with particular emphasis on specific signs of acute dystonic emphasis on specific signs of acute dystonic reaction, parkinsonism, akathisia and tardreaction, parkinsonism, akathisia and tardive dyskinesia. The following rating scales ive dyskinesia. The following rating scales were used to assess the severity of extrapyrwere used to assess the severity of extrapyramidal symptoms ( (Fleischhacker et al et al, 1991) and the , 1991) and the Barnes Akathisia Scale (Barnes, 1989) . HisBarnes Akathisia Scale (Barnes, 1989) . History of extrapyramidal symptoms on pretory of extrapyramidal symptoms on previous neuroleptic treatment was explored vious neuroleptic treatment was explored in a structured interview developed by our in a structured interview developed by our group, covering the typical symptoms of group, covering the typical symptoms of acute dystonic reaction, parkinsonism, acute dystonic reaction, parkinsonism, akathisia and tardive dyskinesia. To check akathisia and tardive dyskinesia. To check the reliability of their answers, participants the reliability of their answers, participants were asked about the consequences of the were asked about the consequences of the development of their movement disorder development of their movement disorder (for example, change in medication or (for example, change in medication or administration of biperiden). In addition, administration of biperiden). In addition, clinical records covering former treatment clinical records covering former treatment phases were reviewed to complete the phases were reviewed to complete the information. Family history of movement information. Family history of movement disorders was obtained by means of a disorders was obtained by means of a structured interview developed in our structured interview developed in our department, specifically covering symptoms department, specifically covering symptoms of Parkinson's disease (stiffness of moveof Parkinson's disease (stiffness of movement, gait problems, tremor, change in ment, gait problems, tremor, change in facial expression, lateralisation of sympfacial expression, lateralisation of symptoms), dystonia and psychiatric disorders toms), dystonia and psychiatric disorders in first-degree to third-degree relatives. This in first-degree to third-degree relatives. This structured interview had previously been structured interview had previously been shown to provide reliable data in a large shown to provide reliable data in a large epidemiological study (Klein epidemiological study (Klein et al et al, 1999 (Klein et al et al, ). , 1999 . A diagnosis of a primary movement disor-A diagnosis of a primary movement disorder was only made if the criteria for the disder was only made if the criteria for the disorder were clearly fulfilled by the symptom order were clearly fulfilled by the symptom description given by the patient. Relatives description given by the patient. Relatives were asked to also undergo the structured were asked to also undergo the structured interview whenever possible. interview whenever possible.
Statistical procedure Statistical procedure
Pearson's chi-squared tests for indepenPearson's chi-squared tests for independence were performed to investigate the dence were performed to investigate the relationship between categorical outcome relationship between categorical outcome variables (lifetime occurrence of extrapyrvariables (lifetime occurrence of extrapyramidal symptoms, including reported and amidal symptoms, including reported and currently observed symptoms; reported currently observed symptoms; reported extrapyramidal symptoms during previous extrapyramidal symptoms during previous treatment phases; currently observed treatment phases; currently observed extrapyramidal symptoms; extrapyramidal symptoms; extrapyramiextrapyramidal symptoms on typical neuroleptic dal symptoms on typical neuroleptic medication; extrapyramidal symptoms medication; extrapyramidal symptoms on atypical neuroleptic medication; lifeon atypical neuroleptic medication; lifetime occurrence and currently observed time occurrence and currently observed acute dystonic reaction, parkinsonism, acute dystonic reaction, parkinsonism, akathisia and tardive dyskinesia) and akathisia and tardive dyskinesia) and possible categorical predictor variables possible categorical predictor variables (gender; age; psychiatric diagnostic cate-(gender; age; psychiatric diagnostic category; dosage range; duration of exposure gory; dosage range; duration of exposure to any neuroleptic medication; duration to any neuroleptic medication; duration of exposure to typical neuroleptic mediof exposure to typical neuroleptic medication; duration of exposure to atypical cation; duration of exposure to atypical neuroleptic medication; positive family neuroleptic medication; positive family history of primary movement disorder). history of primary movement disorder). To achieve the required expected cell To achieve the required expected cell frequency of more than 5 in frequency of more than 5 in w w 2 2 -tests, we -tests, we defined three different age groups: 18-40 defined three different age groups: 18-40 years, 41-60 years and years, 41-60 years and 4 460 years. For 60 years. For the same reason, duration of exposure to the same reason, duration of exposure to neuroleptic medication was categorised neuroleptic medication was categorised as as 5 56 months, 6 months to 5 years, 6 months, 6 months to 5 years, and and 4 45 years. For easier comparison, 5 years. For easier comparison, drug dosages were defined as low, meddrug dosages were defined as low, medium or high, based on current clinical ium or high, based on current clinical practice. Chi-squared values are reported practice. Chi-squared values are reported with two-tailed probabilities. Relationwith two-tailed probabilities. Relationships between possible predictor and outships between possible predictor and outcome variables with come variables with P P5 50.5 revealed by 0.5 revealed by w w 2 2 -tests were entered in a step-wise logis--tests were entered in a step-wise logistic regression analysis to identify predicted tic regression analysis to identify predicted probabilities for extrapyramidal symptoms probabilities for extrapyramidal symptoms (probability to enter at 0.05). By use of a (probability to enter at 0.05). By use of a logistic regression analysis, all predictor logistic regression analysis, all predictor variables are considered within one testing variables are considered within one testing procedure, including intercorrelations, procedure, including intercorrelations, which reduces the probability of type I which reduces the probability of type I errors. All statistical procedures were pererrors. All statistical procedures were performed using the Statistical Package for formed using the Statistical Package for the Social Sciences (version 11.0). the Social Sciences (version 11.0).
RESULTS RESULTS
Demographic and clinical data are listed in Demographic and clinical data are listed in Table 1 . Most patients (62%) had been Table 1 . Most patients (62%) had been admitted for treatment of a psychotic disadmitted for treatment of a psychotic disorder: schizophrenia or schizophreniform order: schizophrenia or schizophreniform disorder ( disorder (n n¼50), schizoaffective disorder 50), schizoaffective disorder ( (n n¼10) or delusional disorder ( 10) or delusional disorder (n n¼2). Four-2). Fourteen patients were receiving neuroleptic teen patients were receiving neuroleptic treatment for an organic psychiatric disortreatment for an organic psychiatric disorder: substance-induced psychotic episodes der: substance-induced psychotic episodes ( (n n¼10), delirium ( 10), delirium (n n¼3) or organic delu-3) or organic delusional disorder ( sional disorder (n n¼1). Eighteen patients 1). Eighteen patients were treated for an affective disorder: uniwere treated for an affective disorder: unipolar depressive disorder with psychotic polar depressive disorder with psychotic symptoms ( symptoms (n n¼10), bipolar disorder with 10), bipolar disorder with psychotic symptoms ( psychotic symptoms (n n¼8; five manic and 8; five manic and three depressive episodes). Six patients three depressive episodes). Six patients had other psychiatric disorders: borderline had other psychiatric disorders: borderline or combined personality disorder ( or combined personality disorder (n n¼5) or 5) or dissociative disorder ( dissociative disorder (n n¼1). Analysis of 1). Analysis of variance including variance including post hoc post hoc comparisons comparisons revealed that patients with an affective disrevealed that patients with an affective disorder were significantly older than patients order were significantly older than patients from the other groups ( from the other groups (F F¼3.89, d.f. 3.89, d .f.¼3, 3, P P¼0.01), who did not differ significantly 0.01), who did not differ significantly with respect to age. The distribution of with respect to age. The distribution of men and women differed significantly bemen and women differed significantly between the diagnostic groups ( tween the diagnostic groups (w w 2 2 ¼17.74, 17.74, d.f. d.f.¼1, 1, P P5 50.01), whereas symptom sever-0.01), whereas symptom severity measured by BPRS scores was similar ity measured by BPRS scores was similar in all groups. More patients had ever been in all groups. More patients had ever been treated with atypical neuroleptic meditreated with atypical neuroleptic medication (87%) than with typical neuroleptics cation (87%) than with typical neuroleptics (64%). (64%).
Lifetime prevalence of Lifetime prevalence of extrapyramidal symptoms extrapyramidal symptoms
Lifetime prevalence of extrapyramidal Lifetime prevalence of extrapyramidal symptoms, including both reported and symptoms, including both reported and currently observed symptoms, was 65% currently observed symptoms, was 65% (Table 2) . Acute dystonic reactions oc- (Table 2) . Acute dystonic reactions occurred most commonly (41%), followed curred most commonly (41%), followed by parkinsonism (37%), akathisia (19%) by parkinsonism (37%), akathisia (19%) and tardive dyskinesia (4%). It should be and tardive dyskinesia (4%). It should be noted that several patients suffered from noted that several patients suffered from more than one type of extrapyramidal more than one type of extrapyramidal symptom. Of those who had experienced symptom. Of those who had experienced such symptoms, more patients had been such symptoms, more patients had been exposed to typical than to atypical mediexposed to typical than to atypical medication. Details of mean age and distribution cation. Details of mean age and distribution of gender are given in Table 2 . of gender are given in Table 2 .
Currently observed Currently observed extrapyramidal symptoms extrapyramidal symptoms
At the time of examination, most patients At the time of examination, most patients were taking an atypical neuroleptic mediwere taking an atypical neuroleptic medication (Table 3) . Extrapyramidal sympcation (Table 3) . Extrapyramidal symptoms were diagnosed in 34% of patients. toms were diagnosed in 34% of patients.
The most commonly observed symptom The most commonly observed symptom was parkinsonism (19%), followed by was parkinsonism (19%), followed by acute dystonic reaction (15%), akathisia acute dystonic reaction (15%), akathisia (5%) and tardive dyskinesia (3%). Again, (5%) and tardive dyskinesia (3%). Again, some patients were diagnosed with more some patients were diagnosed with more than one type of extrapyramidal symptom. than one type of extrapyramidal symptom. Table 3 gives further clinical characteris- Table 3 gives further clinical characteristics and details concerning dosages of tics and details concerning dosages of neuroleptic medication. neuroleptic medication.
Reported symptoms and family Reported symptoms and family history of primary movement history of primary movement disorders disorders 2) reported that they had experienced extrapyramidal that they had experienced extrapyramidal symptoms during previous treatment symptoms during previous treatment phases. Information about the family phases. Information about the family history of primary movement disorders history of primary movement disorders was available for 98 participants and could was available for 98 participants and could be assessed for a total of 1316 relatives, 438 be assessed for a total of 1316 relatives, 438 of whom were first-degree relatives. Thirtyof whom were first-degree relatives. Thirtytwo of these 98 patients (20 men and 12 two of these 98 patients (20 men and 12 women) reported a positive family history, women) reported a positive family history, resulting in a total of 47 affected relatives, resulting in a total of 47 affected relatives, or a prevalence of a primary movement or a prevalence of a primary movement disorder of 3.5% among all relatives. Specidisorder of 3.5% among all relatives. Specifically, the prevalences were 1.1% ( fically, the prevalences were 1.1% (n n¼14) 14) for Parkinson's disease, 1.6% ( for Parkinson's disease, 1.6% (n n¼21) for 21) for tremor and 0.9% ( tremor and 0.9% (n n¼2) for dystonia.
2) for dystonia. Among relatives of patients with lifetime Among relatives of patients with lifetime extrapyramidal symptoms ( extrapyramidal symptoms (n n¼848), the 848), the prevalences were 1.4% ( prevalences were 1.4% (n n¼12) for Parkin-12) for Parkinson's disease, 2.4% ( son's disease, 2.4% (n n¼20) for tremor 20) for tremor and 1.1% ( and 1.1% (n n¼9) for dystonia, whereas 9) for dystonia, whereas among the relatives of patients without lifeamong the relatives of patients without lifetime extrapyramidal symptoms ( time extrapyramidal symptoms (n n¼468), 468), the prevalences were 0.4% ( the prevalences were 0.4% (n n¼2) for 2) for Parkinson's disease, 0.2% ( Parkinson's disease, 0.2% (n n¼1) for tremor 1) for tremor and 0.6% ( and 0.6% (n n¼3) for dystonia. A subgroup 3) for dystonia. A subgroup analysis was performed using data from analysis was performed using data from 27 (2.1%) first-degree relatives of 21 27 (2.1%) first-degree relatives of 21 patients who were seen personally by one patients who were seen personally by one of the investigators. In all of them, the preof the investigators. In all of them, the presence or absence of a primary movement sence or absence of a primary movement disorder was confirmed as established by disorder was confirmed as established by the family history interview (25 relatives the family history interview (25 relatives without a primary movement disorder, 1 without a primary movement disorder, 1 with dystonia and 1 with tremor). In order with dystonia and 1 with tremor). In order to avoid multiple inclusion of patients with to avoid multiple inclusion of patients with more than one affected relative in further more than one affected relative in further statistical analyses, we considered only the statistical analyses, we considered only the closest relative of those patients. This closest relative of those patients. This resulted in 12 patients with a relative with resulted in 12 patients with a relative with Parkinson's disease (5 first-degree relatives Parkinson's disease (5 first-degree relatives and 7 second-degree relatives), 11 patients and 7 second-degree relatives), 11 patients with a relative with tremor (6 first-degree with a relative with tremor (6 first-degree relatives and 5 second-degree relatives) relatives and 5 second-degree relatives) and 9 patients with a relative with dystonia and 9 patients with a relative with dystonia (7 first-degree relatives and 2 second-degree (7 first-degree relatives and 2 second-degree relatives). relatives).
Relationship between possible
Relationship between possible predictor and outcome variables predictor and outcome variables Table 4 shows that the 0.03). Table 4 shows that the prevalence of these four related outcome prevalence of these four related outcome variables was higher in participants with a variables was higher in participants with a positive family history than in patients with positive family history than in patients with a negative history. Furthermore, lifetime a negative history. Furthermore, lifetime prevalence of acute dystonic reaction was prevalence of acute dystonic reaction was related to the subtype of primary movement related to the subtype of primary movement disorders occurring in relatives ( disorders occurring in relatives (w w 2 2 ¼8.27, 8.27, d.f. d.f.¼3, 3, P P¼0.04). Lifetime acute dystonic 0.04). Lifetime acute dystonic reaction occurred in 7 of 9 (78%) patients reaction occurred in 7 of 9 (78%) patients with a family history of dystonia, but only with a family history of dystonia, but only in 7 of 12 (58%) patients with a family in 7 of 12 (58%) patients with a family history of Parkinson's disease, 4 of 11 history of Parkinson's disease, 4 of 11 (36%) patients with a family history of (36%) patients with a family history of tremor and 22 of 44 (50%) patients with tremor and 22 of 44 (50%) patients with a negative family history. a negative family history.
Age Age
We further observed a strong relation We further observed a strong relation between age and lifetime prevalence of between age and lifetime prevalence of EPS ( EPS (w w 9.82, d.f.¼2, 2, P P5 50.01). The prevalence 0.01). The prevalence of the three related outcome variables was of the three related outcome variables was higher in the youngest age group than in higher in the youngest age group than in either of the other age groups (Table 4) . either of the other age groups (Table 4) .
Duration of exposure to neuroleptic Duration of exposure to neuroleptic medication medication
The duration of exposure to any neurolep- 14.91, d.f.¼3, 3, P P¼0.01). As summarised in Table 4 , we 0.01). As summarised in Table 4 , we found the prevalence of all statistically found the prevalence of all statistically related outcome variables to increase with related outcome variables to increase with longer duration of neuroleptic medication. longer duration of neuroleptic medication.
For all other relationships between For all other relationships between possible predictor variables (gender, psychipossible predictor variables (gender, psychiatric diagnostic category or dosage range) atric diagnostic category or dosage range) and outcome variables considered in and outcome variables considered in w w 2 2 tests, tests, P P4 40.05. Thus, only the following 0.05. Thus, only the following possible predictor variables were entered possible predictor variables were entered in a logistic regression analysis: family hisin a logistic regression analysis: family history of primary movement disorders; age; tory of primary movement disorders; age; duration of exposure to any neuroleptic duration of exposure to any neuroleptic medication; duration of exposure to typical medication; duration of exposure to typical neuroleptics; and duration of exposure to neuroleptics; and duration of exposure to atypical neuroleptic medication. Occuratypical neuroleptic medication. Occurrence of tardive dyskinesias was excluded rence of tardive dyskinesias was excluded from outcome variables because of the from outcome variables because of the small number of cases identified. small number of cases identified.
Predictors revealed by logistic Predictors revealed by logistic regression analysis regression analysis
We found that lifetime occurrence of EPS We found that lifetime occurrence of EPS (yes or no) could be correctly predicted in (yes or no) could be correctly predicted in 74% of all cases by knowing the duration 74% of all cases by knowing the duration of treatment with typical neuroleptics, and of treatment with typical neuroleptics, and family history of primary movement disorfamily history of primary movement disorders. Lifetime occurrence of acute dystonic ders. Lifetime occurrence of acute dystonic reaction (yes or no) could be predicted in reaction (yes or no) could be predicted in 65% of cases taking into account the expo-65% of cases taking into account the exposure to typical neuroleptic medication and sure to typical neuroleptic medication and age. Both lifetime occurrence of parkinsonage. Both lifetime occurrence of parkinsonism (yes or no) and of akathisia (yes or no) ism (yes or no) and of akathisia (yes or no) were predicted correctly in 72% and 82%, were predicted correctly in 72% and 82%, respectively, by the duration of typical respectively, by the duration of typical neuroleptic medication. Reported EPS (yes neuroleptic medication. Reported EPS (yes or no), regardless of the subtype, were or no), regardless of the subtype, were correctly predicted in 82% of cases by the correctly predicted in 82% of cases by the duration of exposure to typical neuroleptic duration of exposure to typical neuroleptic medication, age and family history of medication, age and family history of primary movement disorders. Currently primary movement disorders. Currently observed EPS (yes or no) were predicted observed EPS (yes or no) were predicted in 68% of all cases by the family history in 68% of all cases by the family history of primary of primary movement disorders. Extrapyramovement disorders. Extrapyramidal symptoms midal symptoms on typical neuroleptic on typical neuroleptic medication (yes or no) could be predicted medication (yes or no) could be predicted in 73% when considering the duration of in 73% when considering the duration of exposure. As can be seen from the regresexposure. As can be seen from the regression coefficients B in Table 5 , the probabilsion coefficients B in Table 5 , the probability for the occurrence of symptoms always ity for the occurrence of symptoms always increased with the duration of exposure to increased with the duration of exposure to neuroleptic medication, younger age and neuroleptic medication, younger age and positive family history. positive family history.
DISCUSSION DISCUSSION
The main purpose of our study was to The main purpose of our study was to identify predictor variables for neurolepticidentify predictor variables for neurolepticinduced extrapyramidal symptoms, for the induced extrapyramidal symptoms, for the first time considering family history of first time considering family history of primary movement disorders. primary movement disorders.
Prevalence rates for Prevalence rates for extrapyramidal symptoms and extrapyramidal symptoms and primary movement disorders primary movement disorders Based on a sample that represents a typical Based on a sample that represents a typical cohort of in-patients with acute psychotic cohort of in-patients with acute psychotic symptoms, we observed a lifetime prevasymptoms, we observed a lifetime prevalence of extrapyramidal symptoms of 65% lence of extrapyramidal symptoms of 65% and a point prevalence of 34%, comparable and a point prevalence of 34%, comparable to rates reported in large epidemiological to rates reported in large epidemiological studies (Ayd, 1961; Swett, 1975 ; Owens studies (Ayd, 1961; Swett, 1975; Owens & Johnstone, 1982) . Compared with these & Johnstone, 1982). Compared with these studies, the mean age of our patients was studies, the mean age of our patients was low, and the rate of patients ever having low, and the rate of patients ever having been treated with atypical neuroleptics been treated with atypical neuroleptics was high (87%). The percentage of patients was high (87%). The percentage of patients who had been exposed to neuroleptics who had been exposed to neuroleptics for less than 6 months was high (38%). for less than 6 months was high (38%). The overall prevalence of about 3% for The overall prevalence of about 3% for primary movement disorders in all relatives primary movement disorders in all relatives seems plausible. Higher prevalence rates seems plausible. Higher prevalence rates of Parkinson's disease, tremor and of Parkinson's disease, tremor and dystonia among relatives of patients with dystonia among relatives of patients with lifetime extrapyramidal symptoms than lifetime extrapyramidal symptoms than among relatives of patients without such among relatives of patients without such symptoms are comparable with results symptoms are comparable with results reported by others, although our study reported by others, although our study was not designed as a population-based was not designed as a population-based case-control study (Marder case-control study (Marder et al et al, 1996; , 1996; Louis Louis et al et al, 2003) . The relatives' diagnoses , 2003). The relatives' diagnoses could be confirmed in a small subgroup. could be confirmed in a small subgroup.
Predictors of extrapyramidal Predictors of extrapyramidal symptoms symptoms
In our sample, logistic regression analysis In our sample, logistic regression analysis revealed that a positive family history had revealed that a positive family history had significant predictive value for the occursignificant predictive value for the occurrence of extrapyramidal symptoms. The rence of extrapyramidal symptoms. The 4 6 8 4 6 8 4 6 9 4 6 9 Table 5  Table 5 Step-wise logistic regression analysis revealing significant predictor variables for occurrences of extrapyramidal symptoms (d.f.
Step-wise logistic regression analysis revealing significant predictor variables for occurrences of extrapyramidal symptoms (d. probability of observed symptoms at the probability of observed symptoms at the time of examination, for which it was the time of examination, for which it was the only predictor, as well as of lifetime prevaonly predictor, as well as of lifetime prevalence of symptoms and reported symptoms, lence of symptoms and reported symptoms, was increased in patients who had a relative was increased in patients who had a relative with a primary movement disorder. The with a primary movement disorder. The strongest predictive value was found for strongest predictive value was found for the duration of treatment with typical neuthe duration of treatment with typical neuroleptics (lifetime occurrence of EPS, acute roleptics (lifetime occurrence of EPS, acute dystonic reaction, parkinsonism, akathisia, dystonic reaction, parkinsonism, akathisia, and EPS on typical neuroleptics) as well as and EPS on typical neuroleptics) as well as with any neuroleptic medication (reported with any neuroleptic medication (reported EPS). The probability of extrapyramidal EPS). The probability of extrapyramidal symptoms increased with longer duration symptoms increased with longer duration of exposure. Furthermore, younger age of exposure. Furthermore, younger age was also a significant predictor for the was also a significant predictor for the occurrence of symptoms, especially for occurrence of symptoms, especially for acute dystonic reaction. acute dystonic reaction.
Positive family history of primary movement Positive family history of primary movement disorders disorders
The finding that a positive family history The finding that a positive family history of primary movement disorders had a of primary movement disorders had a significant impact on the occurrence of significant impact on the occurrence of extrapyramidal symptoms has two main extrapyramidal symptoms has two main implications. First, our results suggest that implications. First, our results suggest that primary and secondary movement disorprimary and secondary movement disorders may share common genetic factors. ders may share common genetic factors. Second, the association with primary Second, the association with primary movement disorders observed in patients movement disorders observed in patients suffering from psychotic symptoms and suffering from psychotic symptoms and developing extrapyramidal symptoms developing extrapyramidal symptoms may represent a dysfunction within a may represent a dysfunction within a common pathway of the dopaminergic common pathway of the dopaminergic system. This system is involved not only system. This system is involved not only in primary and secondary movement disin primary and secondary movement disorders but also in psychotic disorders. orders but also in psychotic disorders. Earlier hypotheses suggest that such sympEarlier hypotheses suggest that such symptoms might represent exacerbated involuntoms might represent exacerbated involuntary movements that are directly related tary movements that are directly related to cerebral dysfunctions underlying psyto cerebral dysfunctions underlying psychotic diseases -i.e. a dysfunction within chotic diseases -i.e. a dysfunction within the dopaminergic system (Ayd, 1961; the dopaminergic system (Ayd, 1961; Owen & Johnstone, 1982) . Indeed, both Owen & Johnstone, 1982) . Indeed, both Kraepelin (1971) and Bleuler (1950) deKraepelin (1971) and Bleuler (1950) described 'spasmodic phenomena in the scribed 'spasmodic phenomena in the musculature' and 'extraordinary movemusculature' and 'extraordinary movements of the tongue and lips' in patients ments of the tongue and lips' in patients with psychosis long before the introducwith psychosis long before the introduction of neuroleptic drugs. Other studies tion of neuroleptic drugs. Other studies have confirmed this observation by the have confirmed this observation by the finding that prevalence and distribution finding that prevalence and distribution of extrapyramidal symptoms were the of extrapyramidal symptoms were the same in treated and never-treated patients same in treated and never-treated patients and depended only on the age at onset and depended only on the age at onset of the psychotic illness (Owen & Johnof the psychotic illness (Owen & Johnstone, 1982; Srinivasan stone, 1982; Srinivasan et al et al, 2001) . , 2001). Further studies should address the quesFurther studies should address the question whether the occurrence of such tion whether the occurrence of such symptoms represents an endophenotype symptoms represents an endophenotype for schizophrenia, as has been shown for schizophrenia, as has been shown for other neurological dysfunctions in for other neurological dysfunctions in neuroleptic-naıve patients with psychosis neuroleptic-naïve patients with psychosis (Gottesman & Gould, 2003) . Genetic (Gottesman & Gould, 2003) . Genetic association studies of candidate genes, such association studies of candidate genes, such as dopamine receptor genes, will be the natas dopamine receptor genes, will be the natural extension of our study to elucidate ural extension of our study to elucidate the hypothesised common underlying the hypothesised common underlying mechanism at the molecular level. mechanism at the molecular level.
Duration of neuroleptic medication Duration of neuroleptic medication
We observed a strong effect of duration We observed a strong effect of duration of exposure to neuroleptic medication, of exposure to neuroleptic medication, especially of typical neuroleptics, on the especially of typical neuroleptics, on the occurrence of extrapyramidal symptoms, occurrence of extrapyramidal symptoms, including the subtypes acute dystonic reacincluding the subtypes acute dystonic reaction, parkinsonism and akathisia. Although tion, parkinsonism and akathisia. Although many authors have proposed such an many authors have proposed such an effect, retrospective studies rarely coneffect, retrospective studies rarely confirmed this notion (Marsalek, 2000) . From firmed this notion (Marsalek, 2000) . From our results, however, it can be assumed our results, however, it can be assumed that the longer the exposure to neuroleptic that the longer the exposure to neuroleptic drugs, the higher the prevalence of these drugs, the higher the prevalence of these symptoms. This finding may support the symptoms. This finding may support the hypothesis of an accumulating toxic effect hypothesis of an accumulating toxic effect of neuroleptic drugs that is suggested to of neuroleptic drugs that is suggested to be higher in the typical drugs than in the be higher in the typical drugs than in the atypicals, with the exception of clozapine atypicals, with the exception of clozapine (Gil-ad (Gil-ad et al et al, 2001 ). An effect of dosage , 2001). An effect of dosage on occurrence of extrapyramidal symptoms on occurrence of extrapyramidal symptoms at the time of examination could not be at the time of examination could not be confirmed. confirmed.
None of the predictor variables entered None of the predictor variables entered in the logistic regression analysis was found in the logistic regression analysis was found to predict the occurrence of extrapyramidal to predict the occurrence of extrapyramidal symptoms in patients taking atypical neusymptoms in patients taking atypical neuroleptics. The significant relation observed roleptics. The significant relation observed in the in the w w 2 2 test between reported symptoms test between reported symptoms and the duration of medication with atypiand the duration of medication with atypical neuroleptics may be interpreted as a cal neuroleptics may be interpreted as a trend. However, the long-term effect of trend. However, the long-term effect of atypical neuroleptics on extrapyramidal atypical neuroleptics on extrapyramidal symptoms may yet not have been verified, symptoms may yet not have been verified, since only a small proportion of patients since only a small proportion of patients had been exposed to these drugs for more had been exposed to these drugs for more than 5 years (10%), and this aspect than 5 years (10%), and this aspect remains a matter of debate (Tarsy remains a matter of debate (Tarsy et al et al, , 2002 (Tarsy et al et al, , ). 2002 .
Other possible predictors: age, Other possible predictors: age, gender and psychiatric diagnosis gender and psychiatric diagnosis
We were able to validate young age as a We were able to validate young age as a predictor for the occurrence of extrapyrapredictor for the occurrence of extrapyramidal symptoms, especially of acute dystomidal symptoms, especially of acute dystonia (Ayd, 1961; Swett, 1975) . This finding nia (Ayd, 1961; Swett, 1975) . This finding gives further support to the genetic influgives further support to the genetic influence on occurrence of these symptoms. In ence on occurrence of these symptoms. In contrast, there is no evidence from our data contrast, there is no evidence from our data for either diagnostic specificity or gender as for either diagnostic specificity or gender as a predictor for the occurrence of symptoms. a predictor for the occurrence of symptoms.
Methodological limitations Methodological limitations
Our study design must be regarded as someOur study design must be regarded as somewhat explorative, since for most of the relawhat explorative, since for most of the relatives the diagnosis of a primary movement tives the diagnosis of a primary movement disorder could only be established through disorder could only be established through the family history interview. This procedure the family history interview. This procedure might have reduced the validity and reliabilmight have reduced the validity and reliability of the data, although special efforts were ity of the data, although special efforts were made to rate a family history as positive made to rate a family history as positive only if the criteria were unambiguously fulonly if the criteria were unambiguously fulfilled. In a clinical setting, this is also the filled. In a clinical setting, this is also the most practical way to gather information most practical way to gather information and decide whether a patient is at risk of deand decide whether a patient is at risk of developing extrapyramidal symptoms because veloping extrapyramidal symptoms because of a positive family history. of a positive family history.
We are aware that the way in which We are aware that the way in which we categorised neuroleptic dosages may we categorised neuroleptic dosages may appear arbitrary. By definition, atypical appear arbitrary. By definition, atypical neuroleptic dosages cannot be converted neuroleptic dosages cannot be converted to chlorpromazine equivalents. We thereto chlorpromazine equivalents. We therefore decided to use a categorisation based fore decided to use a categorisation based on clinical experience. The distribution of on clinical experience. The distribution of dosage ranges in our sample appears readosage ranges in our sample appears reasonable (22% on low, 52% on medium sonable (22% on low, 52% on medium and 26% on high medication dosages). and 26% on high medication dosages). Exact dosages could only be assessed for Exact dosages could only be assessed for the time of examination. the time of examination.
Genetic considerations Genetic considerations
Our data imply two hypotheses. First, our Our data imply two hypotheses. First, our findings underline the notion of genetic susfindings underline the notion of genetic susceptibility for secondary extrapyramidal ceptibility for secondary extrapyramidal symptoms, and second, they suggest posssymptoms, and second, they suggest possible shared genetic factors in primary and ible shared genetic factors in primary and secondary movement as well as in psychotic secondary movement as well as in psychotic disorders. disorders. Patients who have been exposed to long-term typical neuroleptic medication should be switched to an atypical agent even though extrapyramidal symptoms might should be switched to an atypical agent even though extrapyramidal symptoms might not have been observed as yet. not have been observed as yet.
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& & Our study design must be regarded as somewhat explorative owing to the family Our study design must be regarded as somewhat explorative owing to the family history approach. history approach.
& & Our data-set might have been too small to confirm any dosage effect.
Our data-set might have been too small to confirm any dosage effect.
& & The small sample size might also have been the reason why we did not observe the The small sample size might also have been the reason why we did not observe the gender effect described elsewhere of a higher prevalence of acute dystonia in men and gender effect described elsewhere of a higher prevalence of acute dystonia in men and of parkinsonism, akathisia and tardive dyskinesia in women. of parkinsonism, akathisia and tardive dyskinesia in women.
